Clinical Trial Details

Short Title
crizotinib naive adult patients with ALK-activated non-small cell lung cancer
Official Title

A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naive adult patients with ALK-activated non-small cell lung cancer

Description

Participants in this research study have a particular type of lung cancer called ‘ALK positive’ non-small lung cancer and have already performed the pre-screening part of the study, which was the test for ALK status.  Participants in this study will be asked to take LDK378 capsules once a day.  LDK378 is a medicine which has not been approved by the US Food and Drug Administration for the treatment of people with this medical condition.  Approximately 105 patients at about 25 centers from around the world will participate in this study. 

Start Date
June 11, 2013
End Date
November 20, 2013
Gender Preference
None
Age Group
18 - 99 years
Principal Investigator
Taher Abu Hejleh, MD
Contact Info

Pam Zehr, 319-353-8914

Department
Department or Field of Study
Keywords
201301504 ; Abu Hejleh ; cancer ; lung cancer ; non-small cell lung cancer ; Phase2 ;

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks

x